Video

Medicare Part D and Oncology

Author(s):

Lauren Santye, Assistant Editor

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Related Videos
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit: Peter Hansen | stock.adobe.com
Older patient with medical health checkup with cardiologist or geriatric doctor. Woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Related Content
3D rendering of bispecific antibodies in action | Image Credit: © Александр Михайлюк - stock.adobe.com
May 21st 2025

Zanidatamab Plus Chemotherapy Shows Promising Anti-Tumor Activity in Treatment of HER2-Mutated Breast Cancer

Alexandra Gerlach, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Blood sample vial testing MUC1 levels | Image Credit: © luchschenF - stock.adobe.com
May 21st 2025

Study Links MUC1-C to Estrogen Receptor Expression and Endocrine Resistance in HR+/HER2– Breast Cancer

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients
Published: May 20th 2025 | Updated: May 20th 2025

Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients

Alana Hippensteele, Lead Editor
Primary biliary cholangitis -- Image credit: iushakovsky | stock.adobe.com
May 20th 2025

Linerixibat Significantly Improves PBC-Related Cholestatic Pruritus in Adult Patients

Gillian McGovern, Associate Editor